Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
Editas Medicine will host a conference call and webcast on February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and its fourth quarter and full year 2020 results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine will host a conference call and webcast on February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and its fourth quarter and full year 2020 results. Investors can join through the US toll-free number (844) 348-3801 or internationally at (213) 358-0955, using Conference ID 7172199. The webcast will also be available on Editas Medicine's website.
Editas is focused on genome editing technologies, including CRISPR, aimed at developing treatments for serious genetic diseases.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was +2.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2020.
| Conference Call & Webcast Details | |
| Date: | Thursday, February 25, 2021 |
| Time: | 8:00 am Eastern Time |
| Toll Free: | (844) 348-3801 |
| International: | (213) 358-0955 |
| Conference ID: | 7172199 |
| Webcast: | https://edge.media-server.com/mmc/p/hg6sbc5q |
A live webcast of the conference call can be accessed in the Investors section of Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors
Editas Medicine Investor Relations
(617) 401-9052
ir@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.